Dream study: Prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease;Etude clinique du mois. L'étude DREAM: Prévention du diabète de type 2 par le ramipiril et/ou la rosiglitazone chez les personnes dysglycémiques sans maladie cardio-vasculaire

Revue Medicale de Liege

Volumn 61, Issue 10, 2006, Pages 728-732

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular disease; Impaired glucose tolerance; Prevention; Ramipril; Rosiglitazone; Type 2 diabetes

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; PLACEBO; RAMIPRIL; ROSIGLITAZONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RAMIPRIL; THIAZOLIDINEDIONES;

EID: 33847699014     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scheen AJ, Giet D. - Prévention du diabète de type 2, un nouveau défi de santé publique. Rev Med Liège, 2005, 60, 383-390.
2. Scheen AJ, Letiexhe MR, Ernest Ph. - Prévention du diabète de type 2 : style de vie ou médicaments ? Rev Med Liège, 2003, 58, 206-210.
3. Diabetes Prevention Program Research Group. - Reduction in the incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med, 2002, 346, 393-403.
4. Chiasson J-L, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group. - Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-2077.
5. Walter H, Lubben G. - Potential role of oral thiazolidinedione therapy in preservation of beta-cell function in type 2 diabetes mellitus. Drugs, 2005, 65, 1-13.
6. Scheen AJ. - Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège, 2002, 57, 449-452.
7. Scheen AJ. - Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-2565.
8. Buchanan TA, Xiang AH, Peters RK, et al. - Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 2002, 51, 2796-2803.
9. The Diabetes Prevention Program Research Group. - Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes, 2005, 54, 1150-1156.
10. Scheen AJ. - Réduction comparable de l'incidence du diabète de type 2 sous sartan et sous IEC : comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.
11. The DREAM Trial Investigators. - Effect of ramipril on the incidence of diabetes. N Engl J Med, 2006, 355, DOI: 10.1056/NEJMoa065061.
12. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. - Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : a randomised controlled trial. Lancet, 2006, 368, 1096-1105.
13. Ingelfinger JR, Solomon CG. - Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance - Is there still hope ? N Engl J Med, 2006, 355, online.
14. Scheen AJ, Paquot N, Jandrain B. - Comment j'explore ... le risque d'un patient d'évoluer vers un diabète de type 2. Rev Med Liège, 2002, 57, 113-115.
15. Xiang AH, Peters RK, Kjos SL, et al. - Effect of pioglitazone on pancreatic-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes, 2006, 55, 517-522.
16. Scheen AJ, Paquot N. - Récepteurs PPAR-g, nouvelle cible thérapeutique dans les pathologies métaboliques et cardio-vasculaires. Rev Med Liège, 2005, 60, 89-95.
17. Scheen AJ. - Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program ? (Letter). Diabetes Care, 2003, 26, 2701.
18. Diabetes Prevention Program Research Group. - Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care, 2003, 26, 977-980.
19. Tuomiletho J, Wareham N. - Glucose lowering and diabetes prevention : are they the same ? Lancet, 2006, 368, online.
20. Scheen AJ, Lefèbvre PJ. - L'étude PROactive : prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
21. Eddy DM, Schlessinger L, Kahn R. - Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med, 2005, 143, 251-264.